Company: INTS
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001567264-25-000010
Chunk: 34

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 34
---
enciesSTOCKHOLDERS’ EQUITYPreferred stock, par value $.0001. Authorized shares of 15,000,000 as of both December 31, 2024 and 2023, respectively. None issued and outstanding as of both December 31, 2024 and 2023, respectively.— — Common stock, par value $.0001. Authorized shares of 135,000,000 as of both December 31, 2024 and 2023, respectively. Issued and outstanding shares of 15,122,873 and 13,709,377 as of December 31, 2024 and 2023, respectively.2 1 Additional paid-in capital69,699 63,676 Accumulated deficit(66,783)(50,515)Total stockholders’ equity$2,918 $13,162 Total liabilities and stockholders’ equity$4,783 $17,295 

The accompanying notes are an integral part of these financial statements.

F-3

INTENSITY THERAPEUTICS, INC.

STATEMENTS OF OPERATIONS

(in thousands, except share and per share amounts)

Years Ended December 31,20242023Operating expenses:Research and development$10,496 $4,786 General and administrative6,089 3,533 Total operating expenses16,585 8,319 Loss from operations(16,585)(8,319)Other income (expense):Interest income314 324 Interest expense- (305)Loss on debt extinguishment- (2,262)Other income, net3 24 Net loss$(16,268)$(10,538)Preferred stock deemed dividend- (1,324)Net loss attributable to common stockholders$(16,268)$(11,862)Loss per share, basic and diluted$(1.17)$(1.38)Weighted average number of shares of common stock, basic and diluted13,906,9738,616,324

The accompanying notes are an integral part of these financial statements.

F-4

INTENSITY THERAPEUTICS, INC.

STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIENCY)

(in thousands, except share amounts)

Series A Redeemable Convertible Preferred StockSeries B Convertible PreferredSeries C Convertible PreferredCommon StockAdditional Paid in CapitalAccumulated Def